RGT Wealth Advisors’s Novo Nordisk NVO Stock Holding History

RGT Wealth Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-114	Closed	-$6K	–	261
2021 Q4	$6K	Buy	+114	New	+$6.18K	﹤0.01%	252

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

RGT Wealth Advisors's NVO Position: Q1 2022 in Review

RGT Wealth Advisors sold out of Novo Nordisk (NVO) in Q1 2022, closing a stake of 114 shares — an estimated $6K sold.

RGT Wealth Advisors first reported a position in NVO in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 902 funds tracked by Wall St. Rank hold NVO as of Q1 2022.

RGT Wealth Advisors reported no remaining Novo Nordisk position as of Q1 2022 after selling out during the quarter.
RGT Wealth Advisors sold 114 Novo Nordisk shares in Q1 2022, an estimated $6K.
RGT Wealth Advisors first reported a position in Novo Nordisk in Q4 2021 and held it in 1 quarter.
RGT Wealth Advisors's Novo Nordisk position peaked at $6K in Q4 2021.
902 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2022.

Based on RGT Wealth Advisors's 13F filing for Q1 2022, filed 5 May 2022.